Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease

Nature

Volumn 467, Issue 7311, 2010, Pages 95-98

  He, Gen ^a   Luo, Wenjie ^a   Li, Peng ^b   Remmers, Christine ^a   Netzer, William J ^a   Hendrick, Joseph ^b   Bettayeb, Karima ^a   Flajolet, Marc ^a   Gorelick, Fred ^c,d   Wennogle, Lawrence P ^b   Greengard, Paul ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Intra Cellular Therapies Inc   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA Connecticut Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; GAMMA SECRETASE ACTIVATING PROTEIN; GAMMA SECRETASE INHIBITOR; IMATINIB; NOTCH RECEPTOR; PRESENILIN 1; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; GAMMA-SECRETASE ACTIVATING PROTEIN, MOUSE; NOTCH1 PROTEIN, MOUSE; NOTCH1 RECEPTOR; PEPTIDE FRAGMENT; PIPERAZINE DERIVATIVE; PROTEIN; PYRIMIDINE DERIVATIVE; SECRETASE;

DRUG; ENZYME ACTIVITY; EXPERIMENTAL STUDY; INHIBITOR; NERVOUS SYSTEM DISORDER; PROTEIN; RECOMBINATION;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LINE; CONTROLLED STUDY; DRUG TARGETING; ENZYME SPECIFICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN INTERACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; GENE SILENCING; GENETICS; HUMAN; METABOLISM; RNA INTERFERENCE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BENZAMIDES; CELL LINE; DISEASE MODELS, ANIMAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; PEPTIDE FRAGMENTS; PIPERAZINES; PROTEINS; PYRIMIDINES; RECEPTOR, NOTCH1; RNA INTERFERENCE;

EID: 77956303159     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09325     Document Type: Article

References (22)

1. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766 (2001).
2. Steiner, H., Fluhrer, R. & Haass, C. Intramembrane proteolysis by gamma-secretase. J. Biol. Chem. 283, 29627-29631 (2008).
3. Lathia, J. D., Mattson, M. P. & Cheng, A. Notch: from neural development to neurological disorders. J. Neurochem. 107, 1471-1481 (2008).
4. Wong, G. T. et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876-12882 (2004).
5. Netzer, W. J. et al. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc. Natl Acad. Sci. USA 100, 12444-12449 (2003).
6. Placanica, L. et al. Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes. J. Biol. Chem. 284, 2967-2977 (2009).
7. Dougan, D. A., Mogk, A., Zeth, K., Turgay, K. & Bukau, B. AAA1 proteins and substrate recognition, it all depends on their partner in crime. FEBS Lett. 529, 6-10 (2002).
8. Visintin, R., Prinz, S. & Amon, A. CDC20 and CDH1: A family of substrate-specific activators of APC-dependent proteolysis. Science 278, 460-463 (1997).
9. Lefranc-Jullien, S., Sunyach, C. & Checler, F. APPe, the e-secretase-derived N-terminal product of the b-amyloid precursor protein, behaves as a type I protein and undergoes a-, b-, and c-secretase cleavages. J. Neurochem. 97, 807-817 (2006).
10. Jankowsky, J. L. et al. Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol. Eng. 17, 157-165 (2001).
11. van Es, J. H. et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005).
12. Milano, J. et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 82, 341-358 (2004).
13. Beel, A. J. & Sanders, C. R. Substrate specificity of gamma-secretase and other intramembrane proteases. Cell. Mol. Life Sci. 65, 1311-1334 (2008).
14. Chen, F. et al. TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature 440, 1208-1212 (2006).
15. Thathiah, A. et al. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science 323, 946-951 (2009).
16. Serneels, L. et al. c-secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324, 639-642 (2009).
17. Takami, M. et al. c-secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29, 13042-13052 (2009).
18. Kume, H. & Kametani, F. Abeta 11-40/42 production without gamma-secretase epsilon-site cleavage. Biochem. Biophys. Res. Commun. 349, 1356-1360 (2006).
19. Wiley, J. C., Hudson, M., Kanning, K. C., Schecterson, L. C. & Bothwell, M. Familial Alzheimer's disease mutations inhibit gamma-secretase- mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment. J. Neurochem. 94, 1189-1201 (2005).
20. Bentahir, M. et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 96, 732-742 (2006).
21. Green, R. C. et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. J. Am. Med. Assoc. 302, 2557-2564 (2009).
22. Dai, H., Marbach, P., Lemaire, M., Hayes, M. & Elmquist, W. F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmacol. Exp. Ther. 304, 1085-1092 (2003).